Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to BEAM Therapeutics conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at BEAM's request. I would now like to turn the call over to Holly Manning, Vice President of Investor Relations and External Communications. Please go ahead. Thank you, operator. Good morning, everyone, and welcome to BEAM's conference call to review updates announced this morning in conjunction with our fourth quarter and year-end 2025 financial results. You can access slides for today's call by going to the investor section of our website, beamtx.com. With me on the call today with prepared remarks are John Evans, our Chief Executive Officer, Dr. Amy Simon, our Chief Medical Officer, Dr. Gopi Shankar, our Chief Scientific Officer, Shravan Amani, our Chief Financial Officer, and Dr. Kiran Musunuru from the University of Pennsylvania. Our President, Dr. Giuseppe Pino-Ciaramella, will join for Q&A. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our most recent annual report on Form 10-K and any other filings that we may make with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as r...